Jazz Pharmaceuticals (JAZZ) Common Equity (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Common Equity of $4.5 billion for Q1 2026, up 8.56% year-over-year from $4.2 billion in Q1 2025, and up 4.95% quarter-over-quarter from $4.3 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Common Equity (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $4.5 billion for Q1 2026.
- In Q1 2026, Common Equity rose 8.56% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (up 8.56% YoY), while the FY2025 annual figure was $4.3 billion, up 5.49% from the prior year.
- Common Equity for Q1 2026 stood at $4.5 billion, up from $4.3 billion in the prior quarter.
- The five-year high for Common Equity was $4.5 billion in Q1 2026, with the low at $2.7 billion in Q3 2022.
- The 5-year median for Common Equity is $3.7 billion (2025), against an average of $3.7 billion.
- The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 30.3% in 2022, then advanced 27.11% in 2023.
- Jazz Pharmaceuticals' Common Equity stood at $3.1 billion in 2022, then advanced by 21.11% to $3.7 billion in 2023, then advanced by 9.55% to $4.1 billion in 2024, then grew by 5.49% to $4.3 billion in 2025, then gained by 4.95% to $4.5 billion in 2026.
- Business Quant data shows JAZZ's Common Equity at $4.5 billion in Q1 2026, $4.3 billion in Q4 2025, and $4.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 4.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.80 Bn |
| Mar 31, 2026 | 4.53 Bn |
| Dec 31, 2025 | 4.32 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Jun 30, 2025 | 3.71 Bn |
| Mar 31, 2025 | 4.17 Bn |
| Dec 31, 2024 | 4.09 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Jun 30, 2024 | 3.76 Bn |
| Mar 31, 2024 | 3.70 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.49 Bn |
| Jun 30, 2023 | 3.53 Bn |
| Mar 31, 2023 | 3.34 Bn |
| Dec 31, 2022 | 3.09 Bn |
| Sep 30, 2022 | 2.75 Bn |
| Jun 30, 2022 | 3.20 Bn |
| Mar 31, 2022 | 3.61 Bn |
| Dec 31, 2021 | 3.97 Bn |
| Sep 30, 2021 | 3.94 Bn |